Indeed, we have previously demonstrated that PRAS40 gene therapy with adenoviral vectors improves hepatic insulin sensitivity and reduces systemic hyperglycemia and dyslipidemia in obese mice. The gene discussed is INS; the disease is Hyperglycemia.